araag2/HINT huggingface dataset:
Clinical trial NCT00506987 (phase 2, status: completed)
Conditions: cough
ICD codes: R05.1, R05.2, R05.3, R05.4, R05.9, G44.83, J45.991
Drugs: sch 486757, placebo dose 1
SMILES: O[C@]1(C[C@@H]2CC[C@H](C1)N2C(C1=CC=CC=C1Cl)C1=CC=CC=C1Cl)C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects, 18 to <65 years old, with a history of a dry cough for >6
             months.

          -  By history, evaluation of gastroesophageal reflux disease was done and ruled out by a
             minimum of an 8-week trial of antacid therapy (with a proton-pump inhibitor [PPI]
             given twice daily) with no clinical response in cough.

          -  By history, if there are clinical signs and symptoms of postnasal drip, these signs
             and symptoms will have been treated with a combination of an antihistamine and
             decongestant for a minimum of 8 weeks with no clinical response in cough.

          -  By history, if there are clinical signs and symptoms of asthma, these signs and
             symptoms will have been treated with a combination of an inhaled steroid and a
             short-acting beta-agonist for a minimum of 8 weeks with no clinical response in cough.

        Exclusion Criteria:

          -  Subjects with current evidence of clinically significant pulmonary (especially
             conditions that involve coughing), hematopoietic, cardiovascular, hepatic, renal,
             neurologic, psychiatric, autoimmune, or other disease that precludes the subject's
             participation in the study. In particular, diabetics, uncontrolled hypertensives, and
             subjects with clinically significant cardiomyopathy, prostatic hypertrophy, glaucoma,
             seizure disorders, and psychiatric disorders are to be excluded from participation in
             this study.

          -  Subjects with asthma or chronic obstructive pulmonary disease who require chronic use
             of inhaled or systemic corticosteroids.

          -  Subjects receiving concurrent prohibited medications unless they observe the washout
             period prior to the baseline visit. These medications would include opioid- and
             non-opioid-containing cough suppressants and potent CYP3A inhibitors, such as
             ritonavir, ketoconazole, and clarithromycin. Subjects receiving ACE inhibitors or
             MAOIs will be excluded from the study.

          -  Subjects with a history of allergies to more than two classes of medications.

          -  Current smokers, ex-smokers who stopped smoking in the previous 6 months, or subjects
             with a cumulative smoking history >10 pack-years will be excluded. (Pack-years is a
             way to measure the amount a person has smoked over a long period of time. It is
             calculated by multiplying the number of packs of cigarettes smoked per day by the
             number of years the person has smoked, eg, a 10 pack-year history is equal to smoking
             1 pack per day for 10 years or 2 packs per day for 5 years, etc.)
Clinical trial NCT00077857 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: capecitabine (xeloda®), docetaxel (taxotere®)
SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  women >=18 years of age;

          -  >=1 target lesion;

          -  locally advanced or metastatic breast cancer;

          -  demonstrated resistance to anthracycline;

          -  >=2 regimens of chemotherapy for advanced/metastatic disease.

        Exclusion Criteria:

          -  previous treatment with Xeloda, continuous 5-fluorouracil infusion, or other oral
             fluoropyrimidines;

          -  previous treatment with paclitaxel or docetaxel for advanced/metastatic disease.
Clinical trial NCT00590967 (phase 2, status: terminated)
Conditions: cervical cancer
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: cisplatin
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    due to low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have carcinoma of the uterine cervix.

          -  Patients with squamous cell, adenocarcinoma, and adenosquamous carcinoma are eligible.

          -  International Federation of Gynecology and Obstetrics (FIGO) Stage I to IVA

          -  Patients must have no evidence of metastatic disease outside of the pelvis (except to
             the para-aortic nodes), by PET.

          -  Patients must have a Karnofsky Performance Status of >= 60 and no medical
             contraindications to the administration of chemotherapy.

          -  Age >= 18.

          -  Adequate bone marrow function: white blood cells (WBC) >= 4000/mm3, platelets >=
             100,000 mm3.

          -  Adequate renal function: BUN <= 25 mg/dl, creatinine <= 1.2 mg/dl (urinary diversion
             is permitted to improve renal function).

          -  Patients must have bilirubin <= 1.5 mg/dl.

          -  Signed study-specific informed consent.

        Exclusion Criteria:

          -  No positive lymph nodes by FDG PET

          -  Positive supraclavicular lymph nodes by FDG PET Scan or evidence of more distant
             disease.

          -  FIGO Stage IVB+ Cervical Cancer

          -  No prior (within 5 years) or simultaneous malignancies (other than cutaneous basal
             cell carcinoma).

          -  Karnofsky Performance Status <60.

          -  Patients with significant medical illness preventing the use of full dose chemotherapy
             are excluded.

          -  Patients with the following histologies are excluded: small cell, carcinoid, glassy
             cell, clear cell and adenoid cystic.

          -  Life expectancy < 6 months.

          -  Patients with poorly controlled diabetes mellitus (fasting blood glucose level > 200
             mg/dL) are not eligible.

          -  No prior surgery for treatment of disease other than exploratory laparotomy or biopsy.

          -  No previous systemic chemotherapy.

          -  No pelvic radiation therapy is permitted other than transvaginal irradiation to
             control bleeding.

          -  Pregnant women are ineligible and those of child-bearing potential should practice
             contraception.

          -  Patients with abnormal liver function tests
Clinical trial NCT01631864 (phase 2, status: completed)
Conditions: hypertension, concurrent obesity
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: lcz696, amlodipine, placebo
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent must be obtained before any study assessment is performed.

          -  Males and females of non-childbearing potential ≥ 18 years of age.

          -  Subjects with mild to moderate essential hypertension,

               -  Untreated subjects must have a mean seated SBP (msSBP) ≥ 130 mmHg and < 180 mmHg
                  at screening.

               -  Pre-treated subjects must have a msSBP ≤ 160 mmHg at screening and < 180 mmHg at
                  the end of the washout period.

          -  Waist circumference ≥ 102 cm (men) and ≥ 88 cm (women);

        Exclusion criteria:

          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of enrollment, whichever is longer; or longer if required by local
             regulations.

          -  History of angioedema, drug-related or otherwise

          -  History of hypersensitivity to LCZ696, amlodipine, or drugs of similar chemical
             classes.

          -  Severe hypertension (grade 3 of WHO classification; msDBP ≥100 mmHg and/or msSBP ≥ 180
             mmHg) at screening or at the end of the washout period.

          -  Type 1 or Type 2 diabetes mellitus.

          -  Dyslipidemia requiring pharmacological therapy with a fibrate or nicotinic acid.

          -  Concomitant use of anti-hypertensives, anti-diabetics, or drugs with effects on
             glucose or lipid metabolism for the duration of the study.

        Other protocol defined inclusion/exclusion criteria may apply
Clinical trial NCT01185847 (phase 2, status: completed)
Conditions: non-squamous non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ro5083945, cisplatin, gemcitabine, pemetrexed
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, >/=18 years of age

          -  Advanced (IIIb), metastatic (IV) or recurrent non-small cell lung cancer

          -  At least 1 measurable disease lesion as per RECIST criteria

          -  Confirmed presence of EGFR in tumor tissue

          -  ECOG performance status 0-1

          -  Adequate hematological, renal and liver function

        Exclusion Criteria:

          -  Prior chemotherapy or treatment with another systemic anti-cancer agent

          -  Radiotherapy within the last 4 weeks, except for limited field palliative radiotherapy
             for bone pain relief

          -  Symptomatic or active CNS metastases

          -  Recent history of poorly controlled hypertension (systolic >180mmHg or diastolic
             >100mmHg)

          -  Requirement for steroids > 40 mg prednisolone
Clinical trial NCT00094107 (phase 2, status: completed)
Conditions: melanoma, skin neoplasms
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, C79.2, C44.500, C44.90, D23.9, D48.5, C44.00, C44.301
Drugs: axitinib [ag-013736]
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented melanoma with metastases

          -  No more than 1 prior systemic therapy for metastatic disease (prior adjuvant therapy
             with interferon does not count as prior therapy for metastatic disease)

        Exclusion Criteria:

          -  History of hemoptysis (coughing up of blood)

          -  Brain metastases
Clinical trial NCT00385203 (phase 2, status: completed)
Conditions: gastrointestinal stromal tumors, soft tissue sarcomas
ICD codes: C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, C49.A4, C49.A9
Drugs: azd2171
SMILES: COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological confirmation of GIST which is resistant or intolerant to
             imatinib mesylate, or metastatic STS, which is refractory to standard therapies or for
             which no standard therapy exists

        Exclusion Criteria:

          -  Patients with type I insulin-dependent diabetes or poorly-controlled type II
             insulin-independent diabetes.

          -  Patients with a history of poorly controlled high blood pressure
Clinical trial NCT01324518 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: orm-12741, orm-12741, placebo for orm-12741
SMILES: COC[C@@]1(C)CCCN2CCC3=C(OC4=CC=CC=C34)[C@H]12, COC[C@@]1(C)CCCN2CCC3=C(OC4=CC=CC=C34)[C@H]12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained from the patient and legally acceptable representative, if
             required

          -  Informed consent obtained from the caregiver

          -  Males and and females between 55-90 years

          -  Diagnosis of probable Alzheimer's disease, history of progressive cognitive
             deterioration

          -  Brain imaging consistent with Alzheimer's disease

          -  Mini-mental state examination score 12-21

          -  Treated with donepezil, rivastigmine or galantamine

          -  At least mild level of behavioral symptoms

        Exclusion Criteria:

          -  Other types of dementias

          -  Modified Hachinski Ischemia Score > 4

          -  Use of memantine, antipsychotics, anticholinergic medication and benzodiazepines (at a
             max of 3 nights/week) within 2 months

          -  Changes in antidepressant dosing within 2 months

          -  Use of other psychotropic agents

          -  Myocardial infarction within the past 2 years

          -  Malignancy within the past 5 years

          -  Suicidal ideation, risk of suicide

          -  History of alcoholism or drug abuse within 5 years

          -  Clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal,
             neurological or psychiatric disorder or any other major concurrent illness

          -  Specific findings in brain imaging

          -  Abnormal findings in heart rate, blood pressure, ECG, laboratory tests, physical
             examination; orthostatic hypotension

          -  Blood donation or participation in a drug study within 60 days

          -  Previous AD immunotherapy treatment

          -  Patient cannot complete the computerised cognitive training

          -  Patients who reside in a skilled nursing facility

          -  Patients who are not able to swallow capsules
Clinical trial NCT00259285 (phase 2, status: terminated)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    trial was stopped early due to low enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of non-small-cell carcinoma of the lung

          -  Patients with locally advanced disease or metastatic disease, candidates to surgery
             after evaluation by oncologist and thoracic surgeon

          -  Tumour with possibility of curative surgery

          -  At least one uni-dimensionally measurable lesion

          -  Adequate pulmonary function to perform the planned surgical resection

        Exclusion Criteria:

          -  Active infection (at the investigator's discretion)

          -  Pregnancy or breast-feeding

          -  Serious concomitant illness at the investigator's discretion

          -  Previous diagnosis of malignant disease

          -  They have received treatment during the last 30 days with a drug, other than the study
             drug, that has not received regulatory approval for any indication at the time of
             their entry in the study
Clinical trial NCT00281632 (phase 2, status: completed)
Conditions: peritoneal cancer, ovarian cancer, neoplasms, ovarian, fallopian tube cancer
ICD codes: K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02
Drugs: gw786034
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Eligibility criteria:

        Inclusion criteria:

          -  Confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal
             carcinoma.

          -  Has received one prior platinum-based chemotherapy regimen(cisplatin,carboplatin, or
             oxaliplatin).

          -  Has psychological, familial, sociological or geographical condition that does not
             permit compliance with the protocol.

          -  Is on a specifically prohibited medication or requires these medications during
             treatment with GW786034.

        Exclusion criteria:

          -  Has had any surgery, chemotherapy, hormonal therapy, biologic, immunotherapy, or
             radiotherapy with in the last 28 days and has not recovered from such prior therapy.

          -  Poorly controlled hypertension(systolic 140mmHg or higher or Diastolic 90mmHg or
             higher).

          -  Currently taking warfarin.

          -  Low molecular weight heparin and low-dose warfarin(1mg per day)is permitted.
Clinical trial NCT00141544 (phase 2, status: terminated)
Conditions: menopause
ICD codes: E28.310, E28.319
Drugs: esterified estrogens 1.25 mg and methyltestosterone 2.5 mg, esterified estrogens 1.25 mg
SMILES: [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Reason stopped: 
    lack of enrollment
  
Eligibility criteria:

        Inclusion Criteria:

        Non-hysterectomized, menopausal women between the ages of 35 and 65 years (inclusive) with
        symptoms of estrogen and/or androgen deficiency not currently controlled by estrogen
        therapy as determined by patient report and the Investigator's clinical judgement
Clinical trial NCT00003778 (phase 2, status: completed)
Conditions: ovarian cancer, sarcoma
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: dolastatin 10
SMILES: CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C1=NC=CS1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven recurrent or metastatic soft tissue sarcoma

          -  No rhabdomyosarcoma, Ewing's sarcoma, chondrosarcoma, osteogenic sarcoma,
             mesothelioma, or Kaposi's sarcoma Bidimensionally measurable disease other than
             previously irradiated disease site(s) even if there has been progression within the
             radiation field

          -  Pulmonary nodule(s) at least 1 x 1 cm No brain metastases

        PATIENT CHARACTERISTICS:

          -  Age: 18 and over

          -  Performance status: ECOG 0 or 1

          -  Absolute neutrophil count at least 2,000/mm3

          -  Platelet count at least 100,000/mm3

          -  Bilirubin no greater than 1.5 mg/dL

          -  AST and ALT less than 1.5 times upper limit of normal (ULN) (3 times ULN if liver
             metastases present)

          -  Creatinine no greater than 1.5 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after study

          -  No uncontrolled infection

          -  No history of prior malignancy within the past 5 years except basal cell or squamous
             cell skin cancer, carcinoma in situ of the cervix, or any other malignancy in complete
             remission

        PRIOR CONCURRENT THERAPY:

          -  No more than 1 prior chemotherapy regimen in the adjuvant setting

          -  No prior chemotherapy for metastatic disease

          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)

          -  At least 4 weeks since prior radiotherapy

          -  Recovered from prior surgery
Clinical trial NCT00548093 (phase 2, status: completed)
Conditions: carcinoma, non small cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: pf-00299804, pf-00299804
SMILES: COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced Non-Small Cell Lung Cancer (NSCLC)

          -  Prior treatment with and failure of at least one regimen of chemotherapy and
             erlotinib.

          -  Prior treatment with no more than two chemotherapy regimens, including adjuvant or
             combined modality treatment.

          -  Measurable disease .

          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0-2

          -  Tissue available for KRAS/ EGFR testing

          -  Creatinine clearance > 40 cc/min or serum creat < 1.5 x ULN

        Exclusion Criteria:

          -  Chemotherapy

          -  Radiotherapy

          -  Biological or investigational agents within 4 weeks of baseline disease assessment.

          -  Patients who lack of tolerance of erlotinib therapy.
Clinical trial NCT00234403 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gefitinib and fulvestrant
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed advanced or metastatic breast cancer

          -  postmenopausal females with amenorrhoea > 12 months and an intact uterus

          -  FSH levels within postmenopausal range or have undergone a bilateral oophorectomy

          -  ER &/or PR positive

          -  previous adjuvant hormone therapy > 12 months prior to enrolment

          -  previous adjuvant chemotherapy > 6 months prior to enrolment

          -  measurable disease according to RECIST and/or non measurable bone disease

          -  life expectancy of at least 12 weeks

          -  World Health Organisation (WHO) performance status (PS) of 0 to 1.

        Exclusion Criteria:

          -  Male

          -  life-threatening metastatic visceral disease

          -  evidence of clinically active interstitial lung disease

          -  ER and PR negative

          -  treatment with LHRH analogues < 3 months prior to enrolment

          -  patients who have restarted menses or do not have FSH levels within the postmenopausal
             range

          -  treatment with strontium - 90 (or other radio pharmaceutical) within the previous 3
             months

          -  Treatment with hormonotherapy and/or chemotherapy for advanced disease

          -  extensive radiotherapy to measurable lesions within the last 4 weeks (i.e. >30% of
             bone marrow, e.g. whole of pelvis or half of spine)

          -  currently receiving oestrogen replacement therapy

          -  treatment with a non-approved or experimental drug within 4 weeks before enrolment

          -  absolute neutrophil count (ANC) less than 1.5 x 109/litre (L) or platelets less than
             100 x 109/L , serum bilirubin greater than 1.25 times the upper limit of reference
             range (ULRR, serum creatinine greater than 1.5 mg/dL, alanine aminotransferase (ALT)
             or aspartate aminotransferase (AST) greater than 2.5 times the ULRR if no demonstrable
             liver metastases, or greater than 5 times the ULRR in the presence of liver
             metastases, history of bleeding diathesis or long term or present anticoagulant
             therapy (other than antiplatelet therapy

          -  any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer
             therapy

          -  concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, known

          -  severe hypersensitivity to ZD1839 or fulvestrant or any of the excipients of this
             product.